Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNASDAQ:ALRNNASDAQ:SVRAOTCMKTS:XYNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsALRNAileron Therapeutics$5.06+2.6%$5.41$1.01▼$7.42$85.87M2.2264,769 shs80,550 shsSVRASavara$4.45+5.0%$4.93$1.78▼$5.70$614.76M0.77852,109 shs1.25 million shsXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/AInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-87.23%ALRNAileron Therapeutics+3.79%+16.00%-14.56%+1.86%+230.89%SVRASavara-9.59%-14.52%-12.03%-14.86%+136.87%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AALRNAileron Therapeutics1.3237 of 5 stars3.53.00.00.00.61.70.0SVRASavara3.1122 of 5 stars3.55.00.00.02.61.70.6XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AALRNAileron Therapeutics3.00Buy$19.00275.49% UpsideSVRASavara3.00Buy$8.2084.27% UpsideXYNOXynomic PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest SVRA, XYNO, ADMP, and ALRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00ALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)SVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)XYNOXynomic PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ALatest SVRA, XYNO, ADMP, and ALRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q4 2023ALRNAileron TherapeuticsN/A-$1.54-$1.54-$1.54N/AN/A3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AALRNAileron TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19ALRNAileron TherapeuticsN/A4.174.17SVRASavara0.1915.6615.66XYNOXynomic PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%ALRNAileron Therapeutics90.89%SVRASavara87.93%XYNOXynomic PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%ALRNAileron Therapeutics5.57%SVRASavara4.58%XYNOXynomic Pharmaceuticals86.29%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableSVRASavaraN/A138.15 million131.82 millionOptionableXYNOXynomic Pharmaceuticals27N/AN/ANot OptionableSVRA, XYNO, ADMP, and ALRN HeadlinesSourceHeadlineNon-Hodgkin Lymphoma Pipeline Landscape 2024: Analysis of Over 220 Potential Pharmaceuticals in Developmentfinance.yahoo.com - April 25 at 8:03 AMWatson Pharmaceuticalsforbes.com - February 21 at 10:13 PMElite Pharmaceuticals Inc.wsj.com - February 14 at 12:30 PMHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightfinance.yahoo.com - January 8 at 3:26 PMFennec Pharmaceuticals Inc FENCmorningstar.com - November 1 at 1:58 AMStarfield:Pharmaceuticalsvideogamer.com - September 26 at 5:59 PMDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline Landscapebenzinga.com - September 1 at 8:35 PMGlaxosmithkline Pharmaceuticalslivemint.com - July 8 at 4:16 PMCompany History - Paam Pharmaceuticalsmoneycontrol.com - May 30 at 7:13 AMGlenmark Pharmaceuticals Get USFDA Nod For Human Trial Of Advanced Cancer-Treating Drugoutlookindia.com - March 18 at 3:41 PMDelveInsight Evaluates a Robust High-grade Glioma Pipeline as 120+ Influential Pharma Players to Set Foot in the Domainfinance.yahoo.com - March 13 at 6:05 PMPharmaceutical Secondary Packaging Equipment Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028marketwatch.com - October 7 at 12:35 AMP53 Antagonist Shows Early Activity in Advanced Liposarcomamedpagetoday.com - June 8 at 9:53 PMSelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trialascopubs.org - April 10 at 9:25 AMFollicular Lymphoma Market to Witness Expansion at a 6.85% CAGR during the Study Period [2018-2030], States DelveInsightfinance.yahoo.com - February 9 at 12:55 PMXynomic Pharmaceuticals Holdings Inc (XYNO)investing.com - January 5 at 10:07 PMFollicular Lymphoma Market Size 2021: CAGR Value, Top Manufacturers, Industry Share, Growth, Supply Demand and Forecast till 2026wboc.com - November 10 at 7:29 PMFollicular Lymphoma Drug Landscape Report 2021 - ResearchAndMarkets.comnz.finance.yahoo.com - August 7 at 7:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Aileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Xynomic PharmaceuticalsOTCMKTS:XYNOXynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.